system
A chat on subreddit /r/wallstreetbets
human
He says that other pharma companies have better drugs in the pipeline. 
  
 Just find out if that's true or not.

gpt
The analyst was vouching for ACST, which is a tiny company, with a krill oil based product in development. There is no way they can avoid a multi-year CVOT trial if they want to compete with Vascepa. If ACST's P3 trial is successful, they'll get a label covering &gt;500mg TG level patients. Vascepa's upcoming label will be 20-times bigger.